Rheumatoid arthritis drugs market will grow to $30.4 billion by 2025

19 February 2018

The global rheumatoid arthritis drugs/therapeutics market size was valued at $20.3 billion in 2016.

According to a new report by Grand View Research ( rheumatoid arthritis therapeutics market), the market is anticipated to expand at a compound annual growth rate (CAGR) of 4.6% over the forecast period, reaching $30.4 billion by 2015.

Increasing launches of novel biologics and rising penetration of generic drugs are estimated to provide a significant boost to the market. For instance, introduction of Olumiant (baricitinib) by Eli Lilly (NYSE: LLY) in 2017 is likely to fuel revenue growth in Japan. Similarly, upadacitinib, a novel JAK1-selective inhibitor by AbbVie (NYSE: ABBV), is awaiting approval by 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK